YI

111 Inc
YI

$1.19

5.31%

Market Cap: 102M

About: 111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

Employees: 1,520

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

0.07% less ownership

Funds ownership: 2.04% [Q4 2023] → 1.97% (-0.07%) [Q1 2024]

6% less funds holding

Funds holding: 17 [Q4 2023] → 16 (-1) [Q1 2024]

26% less capital invested

Capital invested by funds: $3.24M [Q4 2023] → $2.4M (-$840K) [Q1 2024]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for YI.

See Analyst Rankings

Financial journalist opinion

111 Announces Appointment of New Auditor

SHANGHAI , July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced the appointment of Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's board of directors and audit committee.

111 Announces Appointment of New Auditor

111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024

SHANGHAI July 17, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on Thursday, July 18, 2024 at 2:00 p.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's business model, strategic goals, competitive landscape and advantages as well as its growth drivers and market opportunities.

111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024

111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility

SHANGHAI , June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced that the Company has entered into a strategic direct supply partnership (the "Partnership") with Beijing Scrianen Pharmaceutical Co., Ltd. ("Scrianen"), a comprehensive pharmaceutical enterprise that integrates research and development, production and marketing.

111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility

111, Inc. (YI) Q1 2024 Earnings Call Transcript

111, Inc. (NASDAQ:YI ) Q1 2024 Earnings Conference Call May 23, 2024 7:30 AM ET Company Participants Junling Liu - Co-Founder, Chairman and CEO Luke Chen - CFO, 111's Major Subsidiary Haihui Wang - COO Conference Call Participants Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the company are Dr. Gang Yu, Co-Founder and Executive Chairman; Mr.

111, Inc. (YI) Q1 2024 Earnings Call Transcript

111, Inc. Announces First Quarter 2024 Unaudited Financial Results

Turned to Quarterly Operational Profitability for the First Time Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8% Achieved Positive Operating Cash Flow SHANGHAI , May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Net revenues were RMB3.5 billion (US$488.7 million) and Gross segment profit (1) was RMB 208.5 million (US$ 28.9 million).

111, Inc. Announces First Quarter 2024 Unaudited Financial Results

111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow

SHANGHAI , April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, before the U.S. market opens on Thursday, May 23, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day).

111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow

111, Inc. (YI) Q4 2023 Earnings Call Transcript

111, Inc. (YI) Q4 2023 Earnings Call Transcript

111, Inc. (YI) Q4 2023 Earnings Call Transcript

111, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

SHANGHAI , March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Highlights Net revenues were RMB4.1 billion (US$578.7 million), representing a decrease of 1.0% year-over-year.

111, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

111 to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results- Conference Call to Follow

SHANGHAI , March 1, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2023 ended December 31, 2023, before the U.S. market opens on Thursday, March 21, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 21, 2024 (7:30 PM Beijing Time on the same day).

111 to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results- Conference Call to Follow

111 Announces Receipt of Withdrawal of Going Private Proposal

SHANGHAI , Feb. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it has received a notice dated Feburary 27, 2024 on behalf of the consortium comprising Dr. Gang Yu, co-founder and co-chairman of the Company, Mr. Junling Liu, co-founder, co-chairman and chief executive officer of the Company and certain other investors (collectively, the "Consortium"), stating that the Consortium would withdraw its preliminary non-binding going private proposal dated September 9, 2022 and preliminary non-binding going private proposal dated October 29, 2022 (collectively, the "Proposals").

111 Announces Receipt of Withdrawal of Going Private Proposal

See News Rankings